Subgroup analysis showed that patients with SCAP exhibited higher levels of RELM-β than patients with NSCAP (740.70 (425.30–1063.00) and 209.00 (100.00–513.90), respectively; p < 0.0001). This evidence concerns the gene RETNLB and syringocystadenoma papilliferum.